Credit Suisse Ag Viridian Therapeutics, Inc.\De Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Credit Suisse Ag holds 47,877 shares of VRDN stock, worth $622,879. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,877
Previous 41,066
16.59%
Holding current value
$622,879
Previous $894,000
6.26%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$65.5 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$58.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$50.5 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$49.6 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$47.6 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $519M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...